SARS-CoV-2 Spike RBD Proteins

InvivoGen Kontakt z doradcą
Spike RBD Proteins Spike RBD proteins with His- or Fc-tag in C-terminal
SARS-CoV-2 Spike RBD Proteins

Protein description

The SARS-CoV-2 (2019-nCoV) Spike RBD (receptor binding domain) has been identified as the key viral element allowing the virus docking to the target cells. RDB is recognized by the ACE2 surface membrane receptor [1-3]. RBD is a candidate for subunit prophylactic vaccines against SARS-CoVs [4, 5]. RBD is also at the center of therapeutic approaches, such as the development and testing of small peptide inhibitors or soluble ACE2 to block the SARS-CoV-2 entry into target cells [6].

Spike-RBD-His and Spike-RBD-Fc were generated by fusing the C-terminus of SARS-CoV-2 Spike RBD [R319-F541] to a poly-histidine sequence, and to a human IgG1 Fc region, respectively.

The SARS-CoV-2 viral sequence used is from the Wuhan-Hu-1 (D614) isolate.

These proteins have been produced in CHO cells and purified by affinity chromatography (See Details and Specifications for more information).

Applications

  • Vaccination studies: using combinations of Spike protein antigens and adjuvants
  • Antibody screening: finding anti-Spike antibodies that can neutralize the SARS-CoV-2 infection
  • Inhibitor screening: finding small molecules, or antibodies able to block the SARS-CoV-2 RBD interaction with the ACE2 receptor
  • ACE2 cellular expression screening: in primary isolated cells or transfected cells

Quality control

  • Size and purity confirmed by SDS PAGE
  • Protein validated by ELISA using a coated Anti-SARS-CoV-Spike-RBD hIgM mAb (clone CR3022)

Learn more about SARS-CoV-2 infection cycle, immune responses, and potential therapeutics.

References

  1. Li F., 2016. Structure, function, and evolution of coronavirus spike proteins. Annu. Rev. Virol. 3:237-261.
  2. Li F. et al., 2005. Structure of SARS coronavirus spike receptor-binding domain complexed with receptor. Science. 309:1864-1868.
  3. Walls A.C. et al., 2020. Structure, function, and antigenicity of the SARS-CoV-2 spike glycoprotein. Cell. 181(2):281-292.e6.
  4. Wang N. et al., 2020. Subunit vaccines against emerging pathogenic human coronaviruses. Front. Microbiol. 11:298. DOI: 10.3389/fmicb.2020.00298.
  5. Padron-Regalado E., 2020. Vaccines for SARS-CoV-2: Lessons from other coronavirus strains. Infect. Dis. Ther. DOI: 10.1007/s40121-020-00300-x.
  6. Monteil V.et al., 2020. Inhibition of SARS-CoV-2 infections in engineered human tissues using clinical-grade soluble human ACE2. Cell. 181:1-9.

Podobne produkty

Recombinant human TGF-β1

Recombinant human TGF-β1

InvivoGen
Więcej
SARS-CoV-2 Nucleocapsid Proteins

SARS-CoV-2 Nucleocapsid Proteins

InvivoGen
Więcej
Luciferase tagged SARS-CoV-2 proteins

Luciferase tagged SARS-CoV-2 proteins

InvivoGen
Więcej